What is the role of brigatinib (Alunbrig) in the treatment of non-small cell lung cancer (NSCLC)?

Updated: Aug 21, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Keith K Vaux, MD  more...
  • Print
Answer

Answer

Brigatinib (Alunbrig) was granted accelerated approval by the FDA in April 2017 for ALK-positive metastatic NSCLC in patients who have progressed on or are intolerant to crizotinib. [37]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!